We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 11-20 of 1,413

Federal Court of Appeal clarifies test for double-patenting
  • Smart & Biggar/Fetherstonhaugh
  • Canada
  • May 12 2016

On April 20, 2016, the Federal Court of Appeal issued its decision in Mylan Pharmaceuticals ULC v Eli Lilly Canada Inc, 2016 FCA 119, a case relating


Patenting Polymorphs of Crystals Internationally
  • Bereskin & Parr LLP
  • Canada, European Union, Japan, USA
  • June 27 2016

Polymorphs are patentable subject matter in Canada and the U.S. Our prior article discussed some best practices to differentiate a new polymorph from


CETA Receives Approval - What IP owners need to know
  • Smart & Biggar/Fetherstonhaugh
  • Canada, European Union
  • October 31 2016

Yesterday, Canada and the European Union officially signed the Comprehensive Economic and Trade Agreement (CETA), clearing the way for ratification


Federal Court grants one of three prohibition applications for VIGAMOX eye drops containing moxifloxacin hydrochloride
  • Norton Rose Fulbright Canada LLP
  • Canada
  • June 1 2014

This latest decision from the Federal Court is consistent with a recent trend towards a more literal construction of patent claims. The Court


Federal Court dismisses application for a prohibition order in respect of PATADAY eye drop solution
  • Norton Rose Fulbright Canada LLP
  • Canada
  • March 18 2014

This case concerns a proposed generic version of the brand name drug PATADAY, an eye drop solution used to treat allergic and inflammatory eye


Supreme Court of Canada Reserves Decision on Utility of AstraZeneca's NEXIUM Patent
  • Smart & Biggar/Fetherstonhaugh
  • Canada
  • November 8 2016

The Supreme Court of Canada today heard oral arguments in AstraZeneca v Apotex and reserved its decision. In a case that raises the propriety of the


Transfer pricing decision recently rendered by the Supreme Court of Canada in GlaxoSmithKline, Inc. v. The Queen, 2012 SCC 52
  • Fox Rothschild LLP
  • Canada
  • November 4 2012

Last month the Supreme Court of Canada (SCC) rendered a unanimious decision in GlaxoSmith Kline, supra


Celgene Corp. v. Canada (Attorney General)
  • WeirFoulds LLP
  • Canada
  • February 16 2011

In this case, the Supreme Court of Canada upheld a regulatory board's decision to interpret its statutory mandate with reliance on a consumer protection purpose


Biosimilar Approvals in the US and Canada - the ‘Patent Dance’
  • Bereskin & Parr LLP
  • Canada, USA
  • December 30 2015

The US and Canada each provide an abbreviated pathway (or shortcut) for a biosimilar manufacturer to get a product approved. The shortcut allows for a


Listing patents against combination drugs in Canada ? Changes coming
  • Gowling WLG
  • Canada
  • December 1 2014

On Nov. 26, 2014, Industry Canada announced an important proposed change to the eligibility requirements for listing a patent against a drug in